enGene Therapeutics Inc.
detalimogene
Countdown
450days
Catalyst readout · ~ Sep 30, 2027 estimated
What's at stake
A key catalyst for detalimogene (its lead indication) is expected ~ Sep 30, 2027.
Primary source
· SEC 8-K
verified 15h ago
“confirmation from the Food and Drug Administration (the “FDA”) that the Company’s filing of the Biologics License Application (“BLA”) with the FDA with respect to detalimogene has been completed and accepted by the FDA, provided that such c”